Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals

Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals

Purificación Martínez del Prado,1 Isabel Alvarez-López,2,3 Severina Domínguez-Fernández,4 Arrate Plazaola,5 Oliver Ibarrondo,6 Elena Galve-Calvo,1 Nerea Ancizar-Lizarraga,2,3 María Gutierrez-Toribio,4 Ainhara Lahuerta-Martí...

Full description

Bibliographic Details
Main Authors: Martínez del Prado P, Alvarez-López I, Domínguez-Fernández S, Plazaola A, Ibarrondo O, Galve-Calvo E, Ancizar-Lizarraga N, Gutierrez-Toribio M, Lahuerta-Martínez A, Mar J
Format: Article
Language:English
Published: Dove Medical Press 2018-03-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
early breast cancer
adjuvant chemotherapy
21-gene assay
economic evaluation
Healthcare costs
Online Access:https://www.dovepress.com/clinical-and-economic-impact-of-the-21-gene-recurrence-score-assay-in--peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/clinical-and-economic-impact-of-the-21-gene-recurrence-score-assay-in--peer-reviewed-article-CEOR

Similar Items